Vanguard Group’s FibroBiologics FBLG Stock Holding History

Vanguard Group’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$274K	Sell	60,817 -872	-1%	-$6.14K	﹤0.01%	4052
2025 Q3	$674K	Hold	61,689	–	–	﹤0.01%	3884
2025 Q2	$767K	Sell	61,689 -9,332	-13%	-$168K	﹤0.01%	3820
2025 Q1	$1.28M	Buy	71,021 +25,434	+56%	+$727K	﹤0.01%	3634
2024 Q4	$1.82M	Buy	45,587 +7,015	+18%	+$377K	﹤0.01%	3589
2024 Q3	$2.38M	Buy	38,572 +27,512	+249%	+$1.83M	﹤0.01%	3498
2024 Q2	$1.1M	Buy	+11,060	New	+$2.11M	﹤0.01%	3761

Other funds holding FBLG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ANTB

AMG National Trust Bank Greenwood Village, Colorado $4.61B AUM 19.2% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OAS

Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return

Vanguard Group's FBLG Position: Q4 2025 in Review

Vanguard Group reduced its FibroBiologics (FBLG) stake by 1.4% in Q4 2025, selling an estimated $6.14K and leaving 60,817 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #4052.

Vanguard Group first reported a position in FBLG in Q2 2024 and has held it in 7 quarters since. The position peaked at $2.38M in Q3 2024. 45 funds tracked by Wall St. Rank hold FBLG as of Q4 2025.

Vanguard Group held 60,817 shares of FibroBiologics worth $274K as of Q4 2025.
Vanguard Group sold 872 FibroBiologics shares in Q4 2025, an estimated $6.14K.
FibroBiologics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4052 holding.
Vanguard Group first reported a position in FibroBiologics in Q2 2024 and has held it in 7 quarters since.
Vanguard Group's FibroBiologics position peaked at $2.38M in Q3 2024.
45 funds tracked by Wall St. Rank held FibroBiologics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.